Sevoflurane Market, by Application, by Distribution Channel, and by Region Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

Sevoflurane Market is estimated to be valued at USD 420.3 Mn in 2026 and is expected to reach USD 583.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.8% from 2026 to 2033.

Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether that is used as an inhalational anesthetic for general anesthesia induction and maintenance. It is the fastest-acting volatile anesthetic after desflurane.

Market Dynamics

Market players are focused on launching new technology to help delivery of anesthesia through inhalers, this could contribute to the growth of the global sevoflurane market over the forecast period. For instance, in April 2022, GE Healthcare, a leading global medical technology company, announced that its end-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System has received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA). In the U.S., GE Healthcare is the only manufacturer approved to provide general anesthesia with end-tidal concentration control.

Increasing number of aesthetic surgeries requiring anesthesia, is expected to drive the growth of global sevoflurane market. For instance, in April 2022, The Aesthetic Society, world's leading association dedicated solely to facial and body aesthetic plastic surgery and cosmetic medicine issued its annual Aesthetic Plastic Surgery Statistics, which revealed that aesthetic plastic surgery increased in 2021 in U.S. owing to data acquired using the Society's new, more accurate digital technology. The data shows a large growth in procedures for the face, breasts, and body. Abdominoplasty, buttock augmentation, and liposuction have all seen a 63% surge in popularity since 2020 in U.S. Breast augmentation, augmentation/breast lift, and breast lift/reduction treatments all increased by 48%.

Increasing launches of technology to recycle inhaled anesthetics is expected to fuel the growth over forecast period. For instance, in July 2020, Baxter International Inc., a global leader in the production and delivery of sterile medications, announced a formal agreement with ZeoSys Medical, a medical technology company, to commercialize technology to capture and recycle anesthetic gases. Baxter will have worldwide distribution rights and an exclusive license to commercialize the technology outside of Europe, as well as an exclusive option to acquire ZeoSys Medical, under the terms of the agreement.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global sevoflurane market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Abbott Laboratories, Baxter, Piramal Pharma Solutions, Manus Aktteva Biopharma LLP, Maruishi Pharmaceutical Co.,Ltd., Lunan Pharmaceutical Group, Abbvie, Wellona Pharma, Rewine Pharmaceutical, and Troikaa Pharmaceuticals Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global sevoflurane market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global sevoflurane market.

Detailed Segmentation:

• Global Sevoflurane Market, By Application (Revenue, USD Mn, 2021 - 2033)
• Induction
• Maintenance
• Global Sevoflurane Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Sevoflurane Market, By Region (Revenue, USD Mn, 2021 - 2033)
• North America
  • By Country:
    • U.S.
    • Canada
• Latin America
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
• Asia Pacific
  • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
• Abbott Laboratories
• Baxter
• Piramal Pharma Solutions
• Manus Aktteva Biopharma LLP
• Maruishi Pharmaceutical Co.,Ltd.
• Lunan Pharmaceutical Group
• Abbvie
• Wellona Pharma
• Rewine Pharmaceutical
• Troikaa Pharmaceuticals Limited